Skip to main content

Table 2 OAT patients’ HRQoL and self-perceived health at baseline and follow up as measured by the EQ-5D-5L

From: Health-related quality of life of long-term patients receiving opioid agonist therapy: a nested prospective cohort study in Norway

  EQ-5D-5L VAS, baseline EQ-5D-5L VAS, baselinea EQ-5D-5L VAS, follow-up EQ-5D-5L Index EQ-5D-5L Index EQ-5D-5L Index
  n 609 n 245 n 245 n 609, baseline n 245, baselinea n 245, follow-up
  Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD
Overall 57 22 57 22 59 22 0.699 0.250 0.691 0.237 0.729 0.237
Gender
 Female 56 23 57 25 57 23 0.653 0.260 0.613 0.273 0.669 0.261
 Male 57 22 57 21 60 22 0.718 0.243 0.716 0.220 0.748 0.226
Age group
 < 25 58 18 55 19 61 25 0.787 0.164 0.766 0.211 0.678 0.390
 26–40 61 22 59 22 60 22 0.724 0.242 0.689 0.234 0.745 0.205
 41–60 54 22 55 22 58 22 0.684 0.253 0.686 0.238 0.716 0.253
 ≥61 51 23 56 16 58 16 0.613 0.292 0.714 0.257 0.754 0.210
OAT medication
 Methadone 53 22 54 21 58 23 0.636 0.260 0.657 0.228 0.686 0.236
 Buprenorphine 58 22 58 22 60 22 0.726 0.235 0.716 0.238 0.758 0.232
 Buprenorphine/
naloxone
65 21 59 30 54 26 0.775 0.242 0.558 0.352 0.737 0.335
  1. OAT Opioid agonist therapy, SD Standard deviation
  2. Index obtained from Devlin, N., Shah, K., Feng, Y., Mulhern, B. and van Hout, B., 2018. Valuing Health-Related Quality of Life: An EQ-5D-5L Value Set for England. Health Economics
  3. aBaseline values for the 245 patients who were eligible for follow-up analysis
  4. The possible range of scores for EQ-5D-5L (0–1, 0 = dead (scores < 0 is possible), 1 = full health) and EQ-VAS (0–100, 0 = worst health imaginable, 100 = best health imaginable
  5. Statistically significant changes are marked in bold (p < 0.05)